

# Telemonitoring in heart failure

<b>Submission date</b> 14/01/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 09/02/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 27/06/2012	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Paul Dendale

### Contact details

Jessa Hospital  
Stadsomvaart 11  
Hasselt  
Belgium  
3500

## Additional identifiers

### Protocol serial number

N/A

## Study information

### Scientific Title

Telemonitoring in heart failure: a multicentre randomised trial

### Study objectives

A heart failure clinic using telemonitoring of weight, blood pressure, heart rate and an automatic symptoms questionnaire allows to reduce the hospitalisation frequency, its duration and mortality. It also increases quality of life and reduces the number of unplanned consultations with the first and second line.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Medical Ethical Committee of Jessa Hospital approved on the 29th November 2007 (ref: 07.70 /cardio07.13)

**Study design**

Prospective randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

Congestive heart failure

**Interventions**

Telemonitoring will consist of daily patient self-measurements of body weight, blood pressure and heart rate with devices that allow automatic transfer of registered data to a web-site. This web-site will trigger E-mail alerts to care providers if data are out of limits, or if data have not been received. The tele-monitoring approach will be assisted by a central call centre, allowed to contact patients if technical problems with devices are suspected. The patients will also be called by an automatic telephone system to answer a short symptom questionnaire once every week.

The total follow-up in control patients, and intervention for other patients, is 6 months.

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

1. Number and duration of hospitalisation after the start of the study
2. Number of unplanned consultations with the heart failure team and GP
3. Number of phone calls (and amount of time spent) between the HF nurse and the patient
4. Quality of life (Minnesota Living with Heart Failure Questionnaire)
5. Mortality rate
6. Number of medication changes
7. Number of changes in alert limits

Measured at entry of study, and after 6 months of follow-up.

**Key secondary outcome(s))**

Blood B-type natriuretic peptide (BNP) content, measured at entry of study, and after 6 months of follow-up.

**Completion date**

01/06/2010

## Eligibility

**Key inclusion criteria**

1. Patients hospitalised for decompensated heart failure, necessitating intravenous (IV) diuretics or augmentation of oral (PO) diuretic, IV inotropic or IV vasodilator. Patients should be stabilised with treatment including angiotensin converting enzyme (ACE) inhibitors (or angiotensin II receptor antagonists [AIIA]), betablockers and diuretics at discharge.
2. Patients should be capable of understanding the aims of the study and to use the telemonitoring system
3. Aged between 50 and 85 years, either sex

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Reversible forms of heart failure
2. Heart failure due to aortic stenosis
3. Isolated right heart failure
4. Patients residing in "elderly homes"
5. Severe renal disease (glomerular filtration rate [GFR] less than 20 ml/min), planned dialysis in the next 6 months
6. Planned implantation of biventricular pacemaker, or cardiac surgery
7. Life expectancy less than 1 year
8. Severe pulmonary disease

**Date of first enrolment**

01/04/2008

**Date of final enrolment**

01/06/2010

## Locations

**Countries of recruitment**

Belgium

**Study participating centre**  
Jessa Hospital  
Hasselt  
Belgium  
3500

## Sponsor information

**Organisation**  
Heart Centre Hasselt vzw (Belgium)

**ROR**  
<https://ror.org/03tw90478>

## Funder(s)

**Funder type**  
Research organisation

**Funder Name**  
Heart Centre Hasselt vzw (Belgium)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2012		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes